It's a bloodbath for shares of Endocyte (ECYT -61%) after analysis of trials on its Precedent...

|By:, SA News Editor

It's a bloodbath for shares of Endocyte (ECYT -61%) after analysis of trials on its Precedent cancer treatment tips off that early conditional approval in the EU appears less certain now. Baird downgrades the company to Neutral, saying "stepping to the sidelines for now makes the most sense."